Panellists in this video:
• Dr Sanjib Banerjee, COO (Biopharma Services), Veeda Lifesciences (MODERATOR)
• Dr Jayashree Aiyar, CSO, Syngene International
• Dr Maloy Ghosh, CSO, Zumutor Biologics
• Dr Rajkumar Aland, Assistant VP, Bioplus Life Science
• Mr Aditya Viswanath Garimella, Associate Director, Corporate Quality Control, OneSource Specialty Pharma
• Dr Amarnath Chatterjee, Head analytical sciences Cipla Biosimilars, Cipla
• Dr Subhra Prakash Chakrabarty, Director and Head, Antibody Engineering, Aurigene Oncology
Key Highlights:
[1] India has the potential to emerge as a global leader in biosimilars and biopharma over the next 10–15 years, building on its strong pharmaceutical manufacturing base
[2] India needs to move beyond its traditional generics-led model and build stronger capabilities in novel drug discovery, development and innovative biologics
[3] Start-ups can accelerate innovation by using CROs/CDMOs through co-development and risk-sharing models instead of spending heavily on their own laboratories and infrastructure
[4] Regulatory reforms, stronger IP policies, greater industry–academia collaboration and better access to advanced technologies are critical to creating an innovation-driven biopharma ecosystem
[5] India needs to develop and retain a highly skilled scientific talent pool, including creating policies that can attract Indian scientists with global drug discovery and development experience back to the country
[6] Rather than betting on a single emerging modality, India should invest across technologies such as ADCs, cell and gene therapies, mRNA and multispecifics, as the next major breakthrough cannot be predicted
[7] Indian pharma companies need a phased transition from generics to innovation, balancing existing revenues with higher-risk investments in novel drug discovery through a structured allocation of resources.